23andMe CEO Responds to FDA Warning Letter

The head of genetic-test maker 23andMe Inc. responded to a Food and Drug Administration warning letter in a blog post Tuesday night, acknowledging the company was behind schedule in addressing FDA concerns but defending the accuracy and value of the company’s tests.

The FDA ordered the Google Inc.-backed company to stop marketing its $99 genetic test in a Nov. 22 letter, saying the company hadn’t secured marketing authorization and expressing concern that inaccurate results could lead consumers to undergo unnecessary health procedures such as breast-cancer surgery. The FDA said 23andMe hadn’t responded to numerous requests for more information, even as the company was launching a national television advertising campaign for the product, which analyzes genetic information from a person’s saliva for clues about disease risk and ancestry.

Read the rest of this post on the original site »


Must-Reads from other Websites

Panos Mourdoukoutas

Why Apple Should Buy China’s Xiaomi

Paul Graham

What I Didn’t Say

Benjamin Bratton

We Need to Talk About TED

Mat Honan

I, Glasshole: My Year With Google Glass

Chris Ware

All Together Now

Corey S. Powell and Laurie Gwen Shapiro

The Sculpture on the Moon

About Voices

Along with original content and posts from across the Dow Jones network, this section of AllThingsD includes Must-Reads From Other Websites — pieces we’ve read, discussions we’ve followed, stuff we like. Six posts from external sites are included here each weekday, but we only run the headlines. We link to the original sites for the rest. These posts are explicitly labeled, so it’s clear that the content comes from other websites, and for clarity’s sake, all outside posts run against a pink background.

We also solicit original full-length posts and accept some unsolicited submissions.

Read more »